For the second quarter of fiscal year 2023 ending June 30 2023, OUTSET MEDICAL ($NASDAQ:OM) reported a total revenue increase of 43.8% compared to the prior year, totaling USD 36.0 million. Reported net income for the same period was -44.0 million, a slight decrease from the prior year’s figure of -43.8 million. These earnings results were reported on August 2 2023.
Analysis – Outset Medical Intrinsic Value
GoodWhale has conducted an analysis of OUTSET MEDICAL‘s financials and has determined that the company’s intrinsic value is around $48.9, as calculated by our proprietary Valuation Line. This figure is significantly higher than the current stock price of $19.4, indicating that the stock is currently undervalued by 60.3%. This provides an opportunity for investors to purchase shares at a discount and benefit from a potential return when the price reaches its true market value. Additionally, OUTSET MEDICAL offers a range of products and services in the healthcare space that could become more profitable as demand for these items increases. This may also contribute to the stock’s appreciation, making it a great long-term investment option for investors. More…
Risk Rating Analysis
Star Chart Analysis
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Outset Medical. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Outset Medical. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Outset Medical. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Outset Medical are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
The company focuses on developing, manufacturing, and commercializing novel medical devices for use in surgery. The company was founded in 2007 and is headquartered in San Jose, California. Treace Medical Concepts Inc is a privately held company that focuses on developing minimally invasive solutions for cardiac and vascular diseases. The company was founded in 2006 and is headquartered in Tampa, Florida. Nemaura Medical Inc is a publicly traded company on the London Stock Exchange’s AIM market under the ticker symbol “NMRD”. The company focuses on the development of wearable medical technology for the continuous monitoring of glucose levels. The company was founded in 2008 and is headquartered in the United Kingdom. CVR Medical Corp is a publicly traded company on the Canadian Securities Exchange under the ticker symbol “CVM”. The company focuses on developing, commercializing, and marketing a non-invasive technology for the early detection of stroke. The company was founded in 2011 and is headquartered in Toronto, Canada.
– Treace Medical Concepts Inc ($NASDAQ:TMCI)
Treace Medical Concepts Inc is a medical device company that focuses on the development and commercialization of products for the treatment of conditions associated with the musculoskeletal and nervous systems, including pain management, orthopedics, and neurosurgery. The company has a market cap of 1.29B as of 2022 and a Return on Equity of -44.68%.
Nemaura Medical Inc is a medical device company that focuses on the development of wearable body sensors. The company’s market cap is 54.47M as of 2022 and its ROE is 292.12%. The company’s products are designed to improve the quality of life for patients with chronic conditions.
Investors should take caution when considering an investment in OUTSET MEDICAL due to the company’s reported total revenue of USD 36.0 million for the second quarter of FY2023, representing a year-over-year increase of 43.8%. Despite this growth, reported net income for the same period was a loss of USD -44.0 million, representing a slight decrease from the prior year’s figure of -43.8 million. Such poor financial performance saw the company’s stock price plummet on August 2 2023 when these earnings were reported, leaving investors to consider if they should invest in the company despite its current financial woes.